Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 5, 2010, Pages 482-491

  Yin, De Tao ^a,b   Wang, Lin ^a   Sun, Jianrui ^a   Yin, Fengyan ^a   Yan, Qingtao ^b   Shen, Rulong ^b   He, Gang ^b   Gao, Jian Xin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Differentiated thyroid carcinoma; Fragile histidine triad; Methylation; Tumor progression

Indexed keywords

ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; THYROID TUMOR; YOUNG ADULT;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; THYROID NEOPLASMS; YOUNG ADULT;

EID: 77956033429     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clinical Chemistry and Laboratory Medicine 2008; 46: 1067-1073.
2. Shaha A. TNM Classification of Thyroid Carcinoma. World Journal of Surgery 2007; 31: 879-887.
3. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS and Seyama T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 1997; 15: 1455-1460.
4. Gao JX. Cancer stem cells: the lessons from precancerous stem cells. J Cell Mol Med 2008; 12: 67-96.
5. Gao J-X and Zhou Q. Epigenetic progenitors in tumor initiation and development. Drug Discovery Today: Disease Models In Press, Corrected Proof
6. Jones PA. Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci 2003; 983: 213-219.
7. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
8. Kim JS, Kim JW, Han J, Shim YM, Park J and Kim D-H. Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer. Cancer Res 2006; 66: 4049-4054.
9. Moulin AP, Clement G, Bosman FT, Zografos L and Benhattar J. Methylation of CpG island promoters in uveal melanoma. Br J Ophthalmol 2008; 92: 281-285.
10. Shen R, Tao L, Xu Y, Chang S, Brocklyn JV and Gao JX. Reversibility of aberrant global DNA and estrogen receptor-a gene methylation distinguishes the colorectal precancer from cancer. Int J Clin Exp Pathol 2009; 2: 21-33.
11. Eun Ju L, Bo Bin L, Jin Wook K, Young Mog S, Hoseok I, Joungho H, Eun Yoon C, Joobae P and Duk-Hwan K. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma. European journal of cancer (Oxford, England: 1990) 2006; 42: 972-980.
12. Yang Y, Takeuchi S, Hofmann WK, Ikezoe T, van Dongen JJM, Szczepanski T, Bartram CR, Yoshino N, Taguchi H and Koeffler HP. Aberrant methylation in promoter-associated CpG islands of multiple genes in acute lymphoblastic leukemia. Leukemia Research 2006; 30: 98-102.
13. Schildhaus HU, Krockel I, Lippert H, Malfertheiner P, Roessner A and Schneider-Stock R. Promoter hypermethylation of p16INK4a, Ecadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol 2005; 26: 1493-1500.
14. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K. The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma-Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers. Cell 1996; 84: 587-597.
15. Kuroki T, Tajima Y, Furui J and Kanematsu T. Common Fragile Genes and Digestive Tract Cancers. Surgery Today 2006; 36: 1-5.
16. Huebner K, Hadaczek P, Siprashvili Z, Druck T and Croce CM. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochimica et Biophysica Acta (BBA)- Reviews on Cancer 1997; 1332: M65-M70.
17. Kisselev LL, Justesen J, Wolfson AD and Frolova LY. Diadenosine oligophosphates (ApnA), a novel class of signalling molecules? FEBS Letters 1998; 427: 157-163.
18. Huebner K, Garrison PN, Barnes LD and Croce CM. THE ROLE OF THE FHIT/FRA3B LOCUS IN CANCER. Annual Review of Genetics 2003; 32: 7-31.
19. Zou M, Shi Y, Farid NR, Al-Sedairy ST and Paterson MC. FHIT Gene Abnormalities in Both Benign and Malignant Thyroid Tumours. European Journal of Cancer 1999; 35: 467-472.
20. Chang TJ, Tsai TC, Wu YL, Yang HM, Chi CW, Yang AH and Lee CH. Abnormal transcripts of FHIT gene in thyroid cancer. Oncol Rep 1998; 5: 245-247.
21. McIver B, Grebe SK, Wang L, Hay ID, Yokomizo A, Liu W, Goellner JR, Grant CS, Smith DI and Eberhardt NL. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin Endocrinol (Oxf) 2000; 52: 749-757.
22. Powell DJ, Jr., Russell JP, Li G, Kuo BA, Fidanza V, Huebner K and Rothstein JL. Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/-mice. Oncogene 2001; 20: 3235-3246.
23. Feinberg AP, Ohlsson R and Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
24. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, Palazzo J, McCue PA, Baffa R and Huebner K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 2005; 24: 1625-1633.
25. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk YM, Rynditch AV and Vozianov AF. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 2008; 265: 250-257.
26. Wu Y, Meng L, Wang H, Xu Q, Wang S, Wu S, Xi L, Zhao Y, Zhou J, Xu G, Lu Y and Ma D. Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis. Oncol Rep 2006; 16: 625-629.
27. Lin J, Yao D-m, Qian J, Wang Y-l, Han L-x, Jiang Y -w, Fei X, Cen J-n and Chen Z-x. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leukemia Research 2008; 32: 1541-1545.
28. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF and Minna JD. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001; 61: 3581-3585.
29. LiVolsi VA A-SJ, Asa SL, Baloch ZW, Sobrinho-Simoes M, Wenig B, DeLellis RA, Cady B. Papillary carcinoma (World Health Organization classification of tumors). In: De Lellis RA LR, Heitz PU, Eng C, editors. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004. p. 57-66.
30. AJCC Cancer Staging Manual: Thyroid. New York: Springer-Verlag, 2002.
31. Iwase H, Omoto Y, Iwata H, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y and Kobayashi S. DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br J Cancer 1999; 80: 1982-1986.
32. Yin DT, Lu XB, Dong MM, Qiu XG and Wang QZ. [Correlation of FHIT expression to cell proliferation and metastasis of laryngeal squamous cell carcinoma]. Ai Zheng 2004; 23: 1338-1341.
33. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821-9826.
34. Holschneider CH, Baldwin RL, Tumber K, Aoyama C and Karlan BY. The Fragile Histidine Triad Gene: A Molecular Link Between Cigarette Smoking and Cervical Cancer. Clinical Cancer Research 2005; 11: 5756-5763.
35. Smith DI, McAvoy S, Zhu Y and Perez DS. Large common fragile site genes and cancer. Seminars in Cancer Biology 2007; 17: 31-41.
36. Dumon KR, Ishii H, Fong LYY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K and Croce CM. FHIT gene therapy prevents tumor development in Fhitdeficient mice. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 3346-3351.
37. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996; 122: 135-140.
38. Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
39. Yeh KT, Chang JG, Chen YJ, Chen ST, Yu SY, Shih MC, Perng LI, Wang JC, Tsai M and Chang CP. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in hepatocellular carcinoma. Cancer Invest 2000; 18: 123-129.
40. Lee S-H, Kim W-H, Kim H-K, Woo K-M, Nam H-S, Kim H-S, Kim J-G and Cho M-H. Altered Expression of the Fragile Histidine Triad Gene in Primary Gastric Adenocarcinomas. Biochemical and Biophysical Research Communications 2001; 284: 850-855.
41. Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M and Motoyama T. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected nonsmall cell lung cancers. Lung Cancer 2007; 58: 131-138.
42. Foja S, Goldberg M, Schagdarsurengin U, Dammann R, Tannapfel A and Ballhausen WG. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas. Liver International 2005; 25: 1202-1208.
43. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M and Ishizaki K. Methylation of the 5' CpG Island of the FHIT Gene Is Closely Associated with Transcriptional Inactivation in Esophageal Squamous Cell Carcinomas. Cancer Res 1998; 58: 3429-3434.
44. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B and Gazdar AF. Aberrant Promoter Methylation Profile of Bladder Cancer and Its Relationship to Clinicopathological Features. Cancer Res 2001; 61: 8659-8663.